Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Seminars in Urology
|
August 1, 1990
Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience
W R Fair, H Scher, H Herr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms
H I Scher, A Sarkis, V Reuter, et al.
The Journal of Urology
|
May 1, 1995
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49
P C Brenner, W J Rettig, M P Sanz-Moncasi, et al.
British Journal of Cancer
|
November 2, 2006
Long-term outcome among men with conservatively treated localised prostate cancer
J Cuzick, G Fisher, M W Kattan, et al.
Genes, Chromosomes & Cancer
|
March 1, 1990
Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification
F Samaniego, E Rodriguez, J Houldsworth, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion
L D Nord, R L Stolfi, A A Alfieri, et al.
Molecular Urology
|
November 4, 2000
Three-dimensional ultrasound analyses of the prostate
E J Feleppa, W R Fair, T Liu, et al.
Cancer Research
|
October 15, 1992
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression
R J Motzer, D M Nanus, P O'Moore, et al.
The Journal of Urology
|
March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion
H I Scher, A Yagoda, H W Herr, et al.
The Journal of Urology
|
March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors
H I Scher, A Yagoda, H W Herr, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Seminars in Urology
|
August 1, 1990
Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience
W R Fair, H Scher, H Herr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms
H I Scher, A Sarkis, V Reuter, et al.
The Journal of Urology
|
May 1, 1995
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49
P C Brenner, W J Rettig, M P Sanz-Moncasi, et al.
British Journal of Cancer
|
November 2, 2006
Long-term outcome among men with conservatively treated localised prostate cancer
J Cuzick, G Fisher, M W Kattan, et al.
Genes, Chromosomes & Cancer
|
March 1, 1990
Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification
F Samaniego, E Rodriguez, J Houldsworth, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion
L D Nord, R L Stolfi, A A Alfieri, et al.
Molecular Urology
|
November 4, 2000
Three-dimensional ultrasound analyses of the prostate
E J Feleppa, W R Fair, T Liu, et al.
Cancer Research
|
October 15, 1992
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression
R J Motzer, D M Nanus, P O'Moore, et al.
The Journal of Urology
|
March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion
H I Scher, A Yagoda, H W Herr, et al.
The Journal of Urology
|
March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors
H I Scher, A Yagoda, H W Herr, et al.
Page
of 6